ASA: Mechanical Removal of Clot No Better Than Best Medical Treatment for Medium or Distal Vessel Occlusion
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 10, 2025 -- Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical treatment for patients with acute ischemic stroke due to medium vessel occlusion, according to two studies published online Feb. 5 in the New England Journal of Medicine to coincide with the annual American Stroke Association International Stroke Conference, held from Feb. 5 to 7 in Los Angeles.
Mayank Goyal, M.D., Ph.D., from the University of Calgary Cumming School of Medicine in Alberta, Canada, and colleagues randomly assigned patients with acute ischemic stroke due to medium vessel occlusion to receive EVT plus usual care or usual care alone (255 and 275 patients, respectively). The researchers found that a modified Rankin scale score of 0 or 1 at 90 days occurred in 41.6 and 43.1 percent of patients in the EVT and usual care groups, respectively (adjusted rate ratio, 0.95; 95 percent confidence interval, 0.79 to 1.15; P = 0.61). Mortality at 90 days was higher in the EVT group (13.3 versus 8.4 percent; adjusted hazard ratio, 1.82; 95 percent confidence interval, 1.06 to 3.12).
Marios Psychogios, M.D., from University Hospital Basel in Switzerland, and colleagues randomly assigned participants with an isolated occlusion of medium or distal vessels to receive EVT plus best medical treatment or best medical treatment alone (271 and 272 patients, respectively). The researchers observed no significant difference in the distribution of modified Rankin scale scores at 90 days in the comparison between EVT plus best medical treatment versus best medical treatment alone. The two groups had similar all-cause mortality and incidence of symptomatic intracranial hemorrhage.
"Identification of persons who might benefit from EVT on the basis of imaging selection and potentially improved techniques or materials should be investigated in future randomized trials," Psychogios and colleagues write.
Several authors from both studies and the author of the editorial disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
Increased Liver Enzyme Levels Seen With Use of Cannabidiol in Adults
THURSDAY, July 10, 2025 -- Use of cannabidiol (CBD) within the range consumers are taking with unregulated CBD products is associated with increased liver enzyme levels, according...
Majority of Patients With Lyme Disease Do Not Follow Up With Clinician
THURSDAY, July 10, 2025 -- Only 34 percent of patients with erythema migrans >5 cm are positive for Lyme disease by a standard two-tier testing (STTT) algorithm, and of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.